Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Patient and physician satisfaction with rofecoxib in osteoarthritis: Results of the EVA (experience with VIOXX in arthritis) survey
Autore:
Steinfeld, S; Poriau, S;
Indirizzi:
Erasme Univ Hosp, Dept Rheumatol, B-1070 Brussels, Belgium Erasme Univ Hosp Brussels Belgium B-1070 matol, B-1070 Brussels, Belgium Elisabeth Ziekenhuis, Dept Rheumatol Rehabil, B-8340 Sijsele Damme, Belgium Elisabeth Ziekenhuis Sijsele Damme Belgium B-8340 Sijsele Damme, Belgium
Titolo Testata:
CURRENT MEDICAL RESEARCH AND OPINION
fascicolo: 2, volume: 17, anno: 2001,
pagine: 81 - 87
SICI:
0300-7995(2001)17:2<81:PAPSWR>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
CYCLOOXYGENASE-2 INHIBITORS; GASTROINTESTINAL TOXICITY; RHEUMATOID-ARTHRITIS; RANDOMIZED TRIAL; CLINICAL-TRIAL; DENTAL PAIN; IBUPROFEN; EFFICACY; CELECOXIB; PLACEBO;
Keywords:
rofecoxib; NSAIDs; osteoarthritis; satisfaction; coxibs; COX-2;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Steinfeld, S Erasme Univ Hosp, Dept Rheumatol, 808 Route De Lennik, B-1070Brussels, Belgium Erasme Univ Hosp 808 Route De Lennik Brussels Belgium B-1070
Citazione:
S. Steinfeld e S. Poriau, "Patient and physician satisfaction with rofecoxib in osteoarthritis: Results of the EVA (experience with VIOXX in arthritis) survey", CURR MED R, 17(2), 2001, pp. 81-87

Abstract

A nationwide survey was undertaken among 74192 patients with osteoarthritis (OA) and 5986 physicians (including 5265 general practitioners [GPs]) in Belgium to evaluate satisfaction with the selective cyclo-oxygenase-2 inhibitor rofecoxib (12.5 or 25 mg, given once a day for an average of 30 days). Rofecoxib was considered by patients to be a very effective treatment for OA, with satisfaction scores of good or very good in the domains of pain, mobility and general satisfaction. More than 80% of GP-treated patients expressed a wish to continue rofecoxib therapy. Preference for rofecoxib was especially strong in patients (n = 45453) who had previously been treated with conventional non-steroidal antiinflammatory drugs (NSAIDs), notably patients who had used diclofenac, ibuprofen and nimesulide. Physicians also expressed high satisfaction with rofecoxib, with more than 80% of surveyed physicians indicating a wish to continue prescribing the drug. The results of this large survey demonstrate a clear preference for rofecoxib over conventional NSAIDs in a substantial majority of OA patients. The satisfactory pain relief and excellent gastrointestinal safety profile of rofecoxib demonstrated in earlier controlled trials are likely to have been factors in patients' preferences for rofecoxib over NSAIDs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/05/20 alle ore 14:38:17